Array Comparative Genomic Hybridization | ACGH Test

Order a test

The array comparative genomic hybridisation (aCGH) RGCC test is used to identify chromosomal abnormalities in a patient that could lead to cancer.

During the test, scientists use a technique called array comparative genomic hybridisation to spot abnormalities in a genome. This insight enables them to assess the likely risk of cancer developing and the potential location of a primary tumour. aCGH RGCC can help clinicians to understand more about a patient’s genes, giving them a powerful tool in the fight against cancer.

Sample of the report Order a test

Test Details

Sample Type

Blood sample

Analysis period

Approx. 2–3 weeks

Cancer type

All types of Cancers

Final results

3–4 weeks

Sample Size

7–10 ml peripheral whole blood

Price*

725€

* The prices of the tests may be an issue of local additional taxes and value added taxes which are dependent of each country’s legislation. The prices may vary in areas that are under the jurisdiction of a distributor. These prices are for the tests only, and they do not include in-office fees such as consultation, blood draws, etc.

Find out more about the science behind RGCC tests

Can brain tumours also be tested with a blood sample?

No, due to the blood-brain barrier, tumour cells cannot enter the bloodstream. This means that we cannot obtain and isolate any tumour cells from the blood sample.

Is it possible to measure circulating tumour cells (CTC) in patients with lymphoma or leukaemia?

Yes, patients with lymphoma or leukaemia can use an RGCC test to measure the number of circulating tumour cells (CTC) they have.

Which test is the most comprehensive test?

The most comprehensive test is the “Onconomics Plus” test. This provides information on the sensitivity or resistance of the patient’s tumour cells to certain cancer drugs and shows options for targeted therapy or an alternative treatment method with organic substances. The test also contains information about the development of the tumour and its potential by identifying epigenetic tumour markers relevant for the therapy, which are crucial for the correct therapeutic approach.

How do online consultations work?

Online consultations will give you the opportunity to speak to any member of the RGCC Network at a time and place that is convenient to you. You will be able to choose from a shortlist of clinicians who best suit your needs.

Will online consultations take place via Zoom, Skype, or another method?

Your chosen clinician will be in touch to make the arrangements and choose the most convenient method.

Didn't find an answer to your question? Contact us directly.

Get in touch

Global Presence

RGCC operates in 23 countries across the world, with bases in all five continents.

Find out more

Array comparative genomic hybridisation (aCGH) RGCC